Pharmagen, Inc.
PHRX
$0.00
$0.000.00%
OTC PK
| 03/31/2014 | 12/31/2013 | 09/30/2013 | 06/30/2013 | 03/31/2013 | |
|---|---|---|---|---|---|
| Revenue | 1.32M | 1.04M | 1.07M | 975.00K | 1.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.32M | 1.04M | 1.07M | 975.00K | 1.72M |
| Cost of Revenue | 583.00K | 401.40K | 400.60K | 275.70K | 686.50K |
| Gross Profit | 736.50K | 641.70K | 673.00K | 699.30K | 1.03M |
| SG&A Expenses | 1.15M | 1.42M | 1.39M | 1.04M | 1.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.73M | 1.82M | 1.79M | 1.32M | 2.05M |
| Operating Income | -410.50K | -775.90K | -713.20K | -342.40K | -327.50K |
| Income Before Tax | -712.60K | -2.31M | -1.35M | -1.50M | -841.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -712.60K | -2.31M | -1.35M | -1.50M | -841.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -712.60K | -2.31M | -1.35M | -1.50M | -841.80K |
| EBIT | -410.50K | -775.90K | -713.20K | -342.40K | -327.50K |
| EBITDA | -380.40K | -742.30K | -686.50K | -322.00K | -308.90K |
| EPS Basic | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 480.38M | 396.01M | 368.41M | 387.79M | 381.27M |
| Average Diluted Shares Outstanding | 480.38M | 396.01M | 368.41M | 387.79M | 381.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |